Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 75Years
All Genders
NCT06454357

A Clinical Study of B007 in the Treatment of Pemphigus.

Led by Shanghai Jiaolian Drug Research and Development Co., Ltd · Updated on 2026-05-05

132

Participants Needed

12

Research Sites

128 weeks

Total Duration

On this page

Sponsors

S

Shanghai Jiaolian Drug Research and Development Co., Ltd

Lead Sponsor

S

Shanghai Pharmaceuticals Holding Co., Ltd

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with pemphigus.

CONDITIONS

Official Title

A Clinical Study of B007 in the Treatment of Pemphigus.

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Voluntarily agree to participate and sign informed consent
  • Clinically diagnosed with pemphigus based on clinical signs
  • Newly diagnosed or experiencing a relapse of pemphigus
  • Able to follow the study protocol as judged by the investigator
Not Eligible

You will not qualify if you...

  • Diagnosed with pemphigus more than 4 years ago
  • Currently using treatment drugs for pemphigus
  • Have other specified diseases or medical history that disqualify participation
  • Have examination abnormalities deemed unsuitable for the study by the investigator
  • History of severe allergy or allergic reaction to human or mouse monoclonal antibodies
  • Known contraindications to oral prescribed drugs
  • Participated in another interventional clinical trial within a specified time before the study
  • Received live vaccine within a specified time before first dose or expected to receive live vaccine shortly after last dose
  • Pregnant or breastfeeding women
  • Fertile women not agreeing to use effective contraception during and after the study
  • Sexually active men not planning to use contraception or planning to donate sperm during or after the study
  • Other conditions considered unsuitable for participation by the researchers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 12 locations

1

Peking University First Hospital

Beijing, China

Actively Recruiting

2

The Second Xiangya Hospital of Central South University

Changsha, China

Actively Recruiting

3

Chengdu Second People's Hospital

Chengdu, China

Actively Recruiting

4

West China Hospital, Sichuan University

Chengdu, China

Actively Recruiting

5

The First Affiliated Hospital of Chongqing Medical University

Chongqing, China

Actively Recruiting

6

The First Affiliated Hospital of Fujian Medical University

Fuzhou, China

Actively Recruiting

7

Dermatology Hospital of Southern Medical University

Guangzhou, China

Actively Recruiting

8

Guangdong Provincial People's Hospital

Guangzhou, China

Actively Recruiting

9

Shandong First Medical University-Affiliated Skin Hospital

Jinan, China

Actively Recruiting

10

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China

Actively Recruiting

11

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, China

Actively Recruiting

12

Henan Provincial People's Hospital

Zhengzhou, China

Actively Recruiting

Loading map...

Research Team

H

Hang Li

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Clinical Study of B007 in the Treatment of Pemphigus. | DecenTrialz